On the morning of August 26, Innovent Biologics (01801.HK) opened more than 6% higher and rose over 10% intraday, reaching a 52‑week high of HKD 112.7 and a market capitalization above HKD 190 billion. The innovative drug sector in Hong Kong strengthened broadly that morning.
The market was voting on a semi‑annual report released the previous evening. On August 25, Innovent disclosed its 2026 interim results: total revenue for the first half was RMB 8.618 billion, up 44.8% year‑on‑year, of which product revenue was RMB 8.201 billion, up 56.7%; IFRS net profit was RMB 1.253 billion, up 50.2% year‑on‑year—half‑year profit already exceeding the full‑year 2025 figure. As of July 31, the company had RMB 30.2 billion in cash on hand.
The numbers themselves were not unexpected. The company, which broke RMB 10 billion in revenue in 2025 and achieved its first full‑year profitability, was expected to continue growing. What truly drove the 52‑week high was another set of figures released alongside the report: by 2030, revenue of RMB 35–40 billion, products launched in the U.S. and Europe, and at least five programs advancing into global multi‑center phase 3 trials.
Three Transformations, Each Harder Than the Last
The day before the report, Innovent celebrated its 15th anniversary. Founder, Chairman, and CEO Yu Dechao divided the 15 years into three phases at the earnings call: in 2016, the company transformed from a pure‑play R&D biotech into a full‑value‑chain pharmaceutical company covering R&D, manufacturing, and commercialization; from 2020 onward, it pursued profitability, reaching RMB 10 billion in revenue and full‑year profitability for the first time in 2025; and in 2026, it began its third transformation—from a leading Chinese biopharmaceutical company to a “globally competitive biopharmaceutical enterprise with initial multinational operational capabilities”.
The first two transformations addressed the question of “how to survive and thrive in China,” and Innovent delivered on both. The third transformation answers a different question: can a company built on China’s medical insurance market and local commercialization system make money in the U.S. and Europe?
The RMB 35–40 billion target is worth examining. In the first half of 2026, Innovent’s total revenue was RMB 8.6 billion—annualized, less than RMB 18 billion. The 2030 target implies a doubling over four years. Chief Financial Officer You Fei explained at the earnings call: “The target is primarily based on existing products, pipelines, and already established partnerships, through organic growth.” In other words, management did not factor in future large‑scale BD deals. This reflects both confidence in the current pipeline’s quality and an honest foundation for the target.
Co‑Co: Keeping the Future in One’s Own Hands
The most noteworthy concept in Innovent’s interim report is Co‑Co (co‑development, co‑commercialization).
Over the past two years, the mainstream model for Chinese innovative drug global expansion has been license‑out: licensing overseas rights to multinational pharmaceutical companies in exchange for upfront payments and milestones, while transferring development risks and costs to the buyer. This model has driven the innovative drug rally over the past year. According to the National Medical Products Administration, the total value of out‑licensing deals by Chinese innovative drug companies in the first half of 2026 was approximately USD 110 billion. Innovent itself has been one of the largest participants: over the past 10 months, the company has reached collaborations with Takeda, Eli Lilly, Pfizer, and others totaling approximately USD 34 billion, involving over 20 pipeline programs. According to the company’s citation of PharmaCube Next Pharma data, this accounts for more than 30% of the total out‑licensing volume by Chinese pharmaceutical companies during the same period.
But within that USD 34 billion, Innovent took a different path for five core programs. For IBI363 (PD‑1/IL‑2α‑biased bispecific antibody), partnered with Takeda, Innovent and Takeda share global development costs at a 40/60 ratio, with “profits or losses” in the U.S. market allocated accordingly. In the USD 10.5 billion collaboration with Pfizer, four products are designated for co‑commercialization and profit‑sharing in the U.S. and Europe. To support this, Innovent has built a U.S. team of approximately 100 people, deeply involved in overseas clinical development, regulatory affairs, and commercialization preparation.
The difference between the two models reflects the rising global influence of local innovative drug companies: license‑out sells the future for a good price upfront; Co‑Co keeps the future in one’s own hands, at one’s own expense. The former offers higher certainty but a lower ceiling; the latter preserves a larger share of profit margins, at the cost of sharing the substantial investment in global phase 3 trials with Takeda and Pfizer—along with the failure risk implied by the phrase “or losses” in the announcements. Innovent’s choice to use profits from its domestic business to fund this tougher path is the most significant strategic decision in this report.
A note of caution on the USD 34 billion figure: this is the aggregate “total package” of upfront payments, milestone payments, and sales royalties—not revenue. The actual BD licensing fee revenue recognized by Innovent in the first half was approximately RMB 300 million. You Fei expects full‑year upfront payment recognition to remain in the USD 200–300 million range. The financial realization of large‑scale partnerships is measured in years; it is more like a long‑term option, exercisable only if the pipeline continues to advance.
Ambition Needs a Pipeline to Support It
Innovent currently has three assets that have entered or are approaching global phase 3, with the combined addressable market estimated by partners at over USD 60 billion.
The most significant is IBI363. This product may eventually succeed PD‑1 monotherapy: it re‑activates immune responses in patients resistant to immunotherapy. Updated data presented at ASCO this year showed that among immunotherapy‑resistant non‑small cell lung cancer patients treated with IBI363, nearly half had survival exceeding 24 months. The global multi‑center phase 3 study MarsLight‑11 is currently underway. A pivotal Chinese phase 2 study in melanoma, head‑to‑head against pembrolizumab, is expected to read out by the end of this year and could support the first NDA. A phase 3 trial in colorectal cancer, a “cold tumor,” has also initiated enrollment.
Gastrointestinal tumors represent the second pillar. IBI343 (tancotamab) is the first CLDN18.2 ADC to enter the NDA stage globally (according to the company). The NDA for third‑line and later gastric/gastroesophageal junction adenocarcinoma was accepted by the NMPA in June this year and granted priority review; phase 3 data were selected for an LBA at this year's ESMO. More significant is pancreatic cancer.More critically, there is pancreatic cancer. Pancreatic cancer is known as the “king of cancers,”and first-line treatment has seen little substantive progress for years. InnoCare plans to initiate a Phase III study of IBI343 for first-line pancreatic cancer in China first, while Takeda will advance its global Phase III trial based on proof-of-concept data.The commercial ceiling for second-line gastric cancer is limited, whereas first-line pancreatic cancer—should it succeed—would be of an entirely different caliber.
The third pillar is in metabolism and ophthalmology. To date, mazdutide is the first GCG/GLP‑1 dual receptor agonist approved globally. Competing in the shadow of semaglutide and tirzepatide, it has established a foothold in China through differentiated benefits such as hepatic fat reduction and uric acid lowering; the 9 mg dose is expected to be approved in the first half of 2027. The company also plans to initiate a phase 3 study evaluating whether mazdutide can reduce cardiovascular risk in patients with atherosclerotic cardiovascular disease—a move indicating that Innovent wants GLP‑1 class drugs to capture both the consumer market and demonstrate their value in serious medicine. In ophthalmology, IBI324 showed superior efficacy in a phase 1b study head‑to‑head against faricimab; partner Ollin will lead the global phase 3 in the second half of the year, with Innovent responsible for patient enrollment in China and South Korea.
Beyond the Good News
Among the flagship products and promising prospects, there is one relatively awkward presence—tafolecimab. It is the first domestic PCSK9 inhibitor included in the National Reimbursement Drug List, but Novartis’s inclisiran, after negotiations, entered the NRDL at the end of last year and took effect on January 1 of this year, with the unit price dropping from nearly RMB 10,000 to below RMB 3,000, requiring only two injections per year—facing enormous competitive pressure on both the payer side and administration convenience.
Novartis management said on an earnings call that inclisiran’s market share in China has already doubled since NRDL inclusion and has the potential to become Novartis’s largest product in China. Innovent’s response is two‑pronged: it plans to submit a marketing application for tafolecimab in first‑line hypercholesterolemia by the end of this year, while also developing the next‑generation monthly formulation IBI3030.
Pressure on the investment side is also reflected in the financial statements. R&D expenditure in the first half was RMB 1.684 billion, up approximately 67% from RMB 1.009 billion in the same period last year; Non‑IFRS net profit was RMB 1.704 billion, with a margin of 19.8%, down 0.6 percentage points from the same period last year; gross margin also edged down from 86.0% to 85.0%. The simultaneous occurrence of high profit growth and a slight margin decline reflects the cost of globalization beginning to take effect: overseas clinical trials, the U.S. team, and multi‑center phase 3 studies each require significant spending.
Management clearly believes the market has not yet fully priced this path. You Fei revealed at the earnings call that the company’s current market capitalization is over USD 20 billion, with over USD 4.5 billion in cash on hand. “After stripping out cash, the value the market is actually assigning to our business and pipeline is significantly undervalued.” This is management’s judgment; it will ultimately be answered by pivotal data in melanoma, phase 3 results in pancreatic cancer, and approvals in the U.S. and Europe.
Fifteen years ago, Yu Dechao founded Innovent in Suzhou with the goal of “developing high‑quality biologics accessible to ordinary people.” The first two transformations fulfilled that mission in the Chinese context. The third transformation aims to deliver on it once again in the U.S. and European markets.